Business Daily Media

The Times Real Estate

.

HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council

Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions

HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today that a collaborative research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions" ("Project") led by Prof.

Zhiwei Chen of The University of Hong Kong ("HKU") on our therapeutic HIV vaccine ("ICVAX") has been awarded HK$66.7 million of funding under the Theme-based Research Scheme ("TRS") of the Research Grants Council ("RGC") for a second 5-year term.

HIV/AIDS are a global health concern, especially significant in Hong Kong. Based on Centre for Health Protection's record, a cumulative total of 12,143 cases of HIV infection and 2,507 cases of AIDS are found in Hong Kong, which have been steadily increasing over the years. The current combination antiretroviral therapy ("cART") target suppressing viral reproduction while this project will further investigate the effect of using our PD-1-enhanced DNA vaccine technologies on immunogenicity.

The Project is led by Professor Zhiwei Chen, Director of the AIDS Institute and Chair Professor of the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of HKU, and the Principal Scientific Advisor of Immuno Cure. The research will be performed in collaboration with Immuno Cure, Chinese University of Hong Kong Phase 1 Clinical Trial Centre, The Third People's Hospital of Shenzhen, and other hospitals in the Mainland where the collaborative team of researchers will investigate and determine the mechanism of PD-1-based DNA vaccine-mediated 7-year cART-free virologic control in SHIV-infected rhesus monkeys; the impact of PD-1-base DNA vaccine on cART-treated people living with HIV-1 ("PLWH"); and the sustained cART-free HIV-1 control using analytical treatment interruption ("ATI") and combinational immunotherapy.

Immuno Cure will contribute to the manufacturing of ICVAX and the design and management of the clinical trials with our aim to determine the ATI amongst the PLWH of ICVAX Phase 1 Trial; to optimise the immunogenicity of ICVAX by conducting a multi-centre Phase 2 Trial; and to determine the immunotherapeutic efficacy by combining ICVAX with other complementary strategies. This Project will strengthen Hong Kong Research Consortium on HIV/AIDS in collaboration with international experts and scientific advisors, and also reveal mechanisms underlying a promising "Made in Hong Kong" immunotherapy in clinical trials. It will ultimately contribute to the understanding of long-term viral control and potential alternative treatment strategies for HIV-1 without cART treatment in future.

Prof. Zhiwei CHEN, Director of AIDS Institute of HKU and the Principal Scientific Advisor of Immuno Cure, said "Preliminary Phase 1 Trial data demonstrated that the HKU patented PD-1-enhanced DNA vaccine ICVAX has shown convincing safety and immunogenicity profiles in PLWH. Our team members are very grateful that this TRS grant will allow us to expand our translational research to benefit more and more PLWH."

Dr. Xia JIN, CEO of Immuno Cure & Co-PI of the Project, said, "We are excited to be a key member of the collaborative research team led by Prof. Chen, with whom we have many years of close working relationship. This TRS-funded research will enhance our understanding of the mechanisms of the immune protection and enable us to further investigate the potential of ICVAX towards functional cure of HIV/AIDS."

Dr. Percy CHENG, Chairman of Immuno Cure, concluded, "Immuno Cure is delighted to have earned RGC's support and recognition of our ICVAX research which is of strategic importance to Hong Kong's long-term development. This milestone allows us to carry out academic collaborative research with HKU's AIDS Institute and other top ranked universities in Hong Kong and the Mainland for the advancement of our combat against HIV/AIDS. We are also grateful for the involvement of all the global expert advisors organised by Prof. Chen."

Hashtag: #ImmunoCure #HKU #AIDS

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher learning in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled "Potentiating Host Immunity for HIV-1 Functional Cure", the institute is currently leading the second 5-year term research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions".

To learn more about HKU and AIDS Institute of HKU, please visit and

About Research Grant Council and Theme-based Research Scheme

To learn more about RGC, please visit:

To learn more about TRS, please visit:

News from Asia

Top 25 Best Places to Work in Europe for 2024 revealed

LONDON, UNITED KINGDOM - Media OutReach Newswire - 7 January 2025 - The Best Places to Work organization is proud to announce the Top 25 Best Places to Work in Europe for 2024, recognizing the mos...

Embrace New Year with Good Luck at Galaxy Macau

A Ultimate Destination for Festive Activities to Ring in a Joyful and Prosperous Year with Family and Friends MACAU SAR - Media OutReach Newswire – 7 January 2025 - As the twelfth lunar month arri...

Ye Xiu Joins Global Fans in Singapore to Ring in New Year's Eve, Yuewen Music Festival Pioneers Novel IP Experiences and Scenarios

SINGAPORE - Media OutReach Newswire - 7 January 2025 - As the clock ticked down the last few hours of 2024, Sentosa Beach in Singapore came alive with excitement. When the voice of Ye Xiu, the be...

Renewal of Dossen Miao Club: Qingmao's Adorable Jouney Across Four Cities

GUANGZHOU, CHINA - EQS Newswire - 8 January 2025 - On December 27, 2024, Dossen Hotel Group officially rebranded its member loyalty program, "Dossen Club," as "Miao Club," with its popular mascot Q...

Chemill Pharma Launches SnoozZ (Melatonin 5 mg & Chamomile 35 mg)

A Clinically-Proven Solution for Better Sleep Amid Rising Insomnia Rates in Hong Kong HONG KONG SAR - Media OutReach Newswire - 8 January 2025 - Chemill Pharma Ltd., an innovative health technolog...

Prince Foundation Partners Again with NTU PEAK ASEAN Program to Address Development Challenges

PHNOM PENH, CAMBODIA - Media OutReach Newswire - 8 January 2025 - Prince Foundation welcomed 10 Nanyang Technological University (NTU) students from Singapore for a three-week program focused on e...

Smart Hospitals: Redefining Global Healthcare with Digital Innovation

NCKUH embraces digitization, revolutionizing patient care through technology TAIPEI, TAIWAN - Media OutReach Newswire - 8 January 2025 - Smart hospitals are at the forefront of a global transforma...

Divineway Fengshui Announces the Launch of Master Louis Cheung’s Book on Taoist Divine Magic

SINGAPORE - Media OutReach Newswire - 8 January 2025 - Divineway Fengshui announces the release of Master Louis Cheung's new book, An Introduction to Liu Ren Divine Magic. The book aims to provide...

Grab Partners London School of Business & Finance to Offer Tertiary Education Programmes for Platform Workers and their loved ones

3 in 5 Grab partners are keen to pursue a Diploma or Degree Grab partners and their loved ones benefit from exclusive admission requirements, and enjoy additional perks including ...

KPMG and SID Unveil Budget 2025 Recommendations to Build a Ready, Refreshed, and Resilient Singapore, Driving Value Creation and Global Leadership

Foster Environmental, Social and Governance (ESG) adoption by Singapore enterprises through national frameworks, grants, and a hub to align with global sustainability standards...

UBH Group Pioneers Australia's Path to Nuclear Sovereignty

Sovereign technology company, UBH Group, has achieved a landmark milestone as the first organisation in the Southern Hemisphere to secure ISO 1944...

The unsung heroes: How MSPs can safeguard SMBs while boosting profitability

In Australia, small-to-medium-sized businesses (SMBs) form the backbone of the economy, accounting for 95% of all businesses. Yet, they remain pri...

Businesses grapple with wage compliance as new laws take effect

Australian businesses are navigating a landscape of rising compliance complexity as new wage theft laws under The Closing Loopholes Acts take hold...

Aerologix Partners with Soar to Create World’s Largest Digital Atlas

Australian drone technology pioneer Aerologix today announced a strategic partnership with digital mapping platform Soar to create what is set to ...

Five signs that AI is growing faster than the internet did

What do Aussie businesses need to do to keep up? There has been mounting chatter that AI is growing even faster than the rapid acceleration we sa...

Protecting Your Small Business from Cyber Threats This Holiday Season

The holiday season brings a surge of online activity for small and medium businesses (SMBs), with increased sales and customer inquiries offering ...

Sell by LayBy